Sabestomig

Phase 1Biologic

PPresage Biosciences

Sabestomig is one of 85 biologic programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Head and Neck Squamous Cell CarcinomaCompleted

LymphomaPhase 1

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 1

Completed

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

Norvir

AbbVie

Preclinical

1 3

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

PEG-Intron

Merck & Co.

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 1Recruiting

Cancer

NCT04541108

Clinical

Trials by Indication[1]

Cancer1 trial

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

Recruiting·PPresage Biosciences·Phase 1·NCT04541108·15 enrolled

Lymphoma1 trial

Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05216835·45 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592

Completed·PPresage Biosciences·Phase 1·NCT06366451·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Sabestomig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sabestomig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sabestomig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Presage Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: PPresage Biosciences

Sabestomig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Cancer1 trial

Lymphoma1 trial

Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News